FDA Oncology Announcements

Anti-TF ADC × Gynecologic × Clear all

2 Announcements

FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

Trial: innovaTV 301
Drug: Tivdak (tisotumab vedotin-tftv) · Anti-TF antibody-drug conjugate
Condition: Gynecologic

FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

Drug: Tivdak (tisotumab vedotin-tftv) · Anti-TF antibody-drug conjugate
Condition: Gynecologic